

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Jun 2026

levetiracetam versus carbamazepine monotherapy in the treatment of focal epilepsy of children

Protocol summary

Summary

The aim of this study is to compare the monotherapy effect of levetiracetam with carbamazepine in the treatment of children with focal epilepsy. For this purpose, children with age over one year and less than sixteen years old with newly diagnosed focal epilepsy, are entered to study. This is a randomized prospective study. Patients with Pseudo- seizures; Skin rash especially Stevens Johnson syndrome; Drug-induced hepatitis; Acute psychosis; Renal disorders; Severe agitation, are excluded from the study. The children are randomly treated by Levetiracetam or Carbamazepine. All patients are followed for the occurrence of seizures and side effects in one and six-month intervals. For investigation of side effects, liver function tests and complete blood count is done for all patients. For other considerable side effects such as drowsiness, restlessness and skin complications, patients are questioned.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2015030821355N1**

Registration date: **2017-01-12, 1395/10/23**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2017-01-12, 1395/10/23

Registrant information

Name

Hosein Eslamiyeh

Name of organization / entity

Shahid Sadoughi University of Medical Science

Country

Iran (Islamic Republic of)

Phone

+98 353724015

Email address

eslamieh@ssu.ac.ir

Recruitment status

Recruitment complete

Funding source

Mashhad University of Medical Sciences

Expected recruitment start date

2014-07-02, 1393/04/11

Expected recruitment end date

2015-03-05, 1393/12/14

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

levetiracetam versus carbamazepine monotherapy in the treatment of focal epilepsy of children

Public title

levetiracetam versus carbamazepine monotherapy in the treatment of focal epilepsy of children

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Children with age over one year and less than sixteen years old with newly diagnosed focal epilepsy, No history of refractory seizures, No history of renal disease, No history of hepatic disease, No history of cerebral palsy, No history of antiepileptic drug consumption. Exclusion criteria: Pseudo- seizures, Skin rash especially Stevens Johnson syndrome, Drug-induced hepatitis, Acute psychosis, Renal disorders, Severe agitation, any other mild side effects that is unbearable

to the patient or parents

Age

From **1 year** old to **16 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Mashhad University of Medical Sciences

Street address

Mashhad University of Medical Sciences, Vakil abad

City

Mashhad

Postal code

9177948976

Approval date

2013-12-03, 1392/09/12

Ethics committee reference number

t-3181

Health conditions studied

1

Description of health condition studied

Epilepsy

ICD-10 code

G40

ICD-10 code description

Episodic diseases

Primary outcomes

1

Description

Occurrence of seizure

Timepoint

Six months from the beginning of study

Method of measurement

Description of patients and parents

Secondary outcomes

1

Description

Rise of liver enzymes

Timepoint

One month after beginning of the study

Method of measurement

Measurement of AST and ALT

2

Description

Skin rash

Timepoint

In the six month from the beginning of the study

Method of measurement

Observation

3

Description

Agitation

Timepoint

In the six month from the beginning of the study

Method of measurement

Parents report

4

Description

Somnolence

Timepoint

In the six month from the beginning of the study

Method of measurement

Parents report

5

Description

Advers blood effects

Timepoint

One month after beginning of study

Method of measurement

CBC examination

Intervention groups

1

Description

Control Group: carbamazepine group: This group will be treated with carbamazepine. In carbamazepine group, the

drug with the dose of 5 mg/kg/day is initiated and increases 5 mg/kg/week. finally, it reaches to the current dose of 15 mg/kg/per day. Then, with the same dose, the drug continues.

Category

Treatment - Drugs

2**Description**

Intervention Group: levetiracetam group: This group will be treated with levetiracetam. In levetiracetam group, the drug with the dose of 10 mg/kg per day is initiated and increases 10 mg/kg/week. finally, it reaches to the current dose of 30 mg/kg/per day. Then, with the same dose, the drug continues.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Ghaem Hospital

Full name of responsible person

Hosein Eslamiyeh

Street address**City**

Mashhad

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Hosein Eslamiyeh

Street address

Ghaem hospital

City

Mashhad

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries**Contact****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Hosein Eslamiyeh

Position

Assistant professor, pediatric neurologist

Other areas of specialty/work**Street address**

Ghaem Hospital

City

Mashhad

Postal code**Phone**

+98 51 3854 3031

Fax**Email**

Eslamieh@ssu.ac.ir

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Ghaem hospital

Full name of responsible person

Hosein Eslamiyeh

Position

Pediatric neurologist. Assistant professor

Other areas of specialty/work**Street address**

Ghaem hospital, Ahmad abad

City

Mashhad

Postal code**Phone**

+98 51 3854 3031

Fax**Email**

Eslamieh@ssu.ac.ir

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Ghaem hospital

Full name of responsible person

Hosein Eslamiyeh

Position

Pediatric neurologist. Assistant professor

Other areas of specialty/work**Street address**

Shahid Sadoughi Hospital, Yazd

City

Yazd

Postal code

8915887857

Phone

+98 35 3822 9104

Fax

+98 35 3822 9104

Email

eslamieh@ssu.ac.ir

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty